Review On Cervical Cancer, Associate Risk, Staging, Screening Tests, Therapies and Vaccination

Over 300,000 people die from cervical cancer worldwide, making it the fourth most frequent malignancy among women. Prolonged infection with high-risk subtypes of the human papillomavirus is the cause of cervical cancer, and the E5, E6, and E7 viral oncoproteins work in tandem with host factors to initiate and sustain the malignant phenotype. The majority of cervical cancer may be prevented, and survival rates are considerably higher when the disease is detected early. It is considered a rare disease in high-income nations with well-established screening and vaccination programs. But in low- and middle-income nations, where resources are scarce, the disease kills women, who frequently have advanced, incurable sickness. Surgical procedures, chemotherapy, and/or radiation therapy are available as treatments, either separately or in combination.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-12-30
DOI
https://doi.org/10.5281/zenodo.14575154
Citations
1
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Review On Cervical Cancer, Associate Risk, Staging, Screening Tests, Therapies and Vaccination

1 citations
Zenodo (CERN European Organization for Nuclear Research)
Cervical Cancer and HPV Research
0.39
article

Review On Cervical Cancer, Associate Risk, Staging, Screening Tests, Therapies and Vaccination

article en
1 citations

Abstract

Over 300,000 people die from cervical cancer worldwide, making it the fourth most frequent malignancy among women. Prolonged infection with high-risk subtypes of the human papillomavirus is the cause of cervical cancer, and the E5, E6, and E7 viral oncoproteins work in tandem with host factors to initiate and sustain the malignant phenotype. The majority of cervical cancer may be prevented, and survival rates are considerably higher when the disease is detected early. It is considered a rare disease in high-income nations with well-established screening and vaccination programs. But in low- and middle-income nations, where resources are scarce, the disease kills women, who frequently have advanced, incurable sickness. Surgical procedures, chemotherapy, and/or radiation therapy are available as treatments, either separately or in combination.

Zenodo (CERN European Organization for Nuclear Research)
No poverty
Openalex Percentile: Top 30%
Cervical Cancer and HPV Research
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Review On Cervical Cancer, Associate Risk, Staging, Screening Tests, Therapies and Vaccination · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS